Compare Crispr Therapeutics AG (CRSP) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Upwork Inc — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Upwork Inc trades at $9.11 (market cap $1.12B). The key difference: Crispr Therapeutics AG is far larger — about 4.4× Upwork Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | UPWK | |
|---|---|---|
Market Cap | $4.97B | $1.12B |
Sector | Health | Industrials |
52-Week High | $76.78 | $22.11 |
52-Week Low | $44.34 | $7.84 |
Enterprise Value | $3.32B | $915.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
UPWK trades at $9.12, up 3.4% today, with a bullish technical signal from moving averages. The company reported $787.78M revenue and $115.43M net income for 2025, with strong profitability margins. Recent news highlights AI integration initiatives and board refreshment, but multiple law firms are investigating potential securities law violations following earnings misses and a guidance cut.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but earnings misses and legal scrutiny pose risks. Revenue growth has slowed, and net cash flow turned negative in 2025. Upside depends on successful AI adoption and execution, while downside risks include ongoing investigations and competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
